Current Report Filing (8-k)
May 15 2017 - 8:22AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 15, 2017
Minerva Neurosciences, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36517
|
|
26-0784194
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
1601 Trapelo Road
Suite 284
Waltham,
MA
|
|
02451
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(Registrants telephone number, including area code): (617) 600-7373
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
On May 15, 2017, Minerva Neurosciences, Inc. (the Company) issued
a press release providing details of the Companys MIN-101 end-of-Phase 2 meeting with the U.S. Food and Drug Administration, and a press release providing an update on the Companys MIN-101 Phase 3 design and development strategy. A copy
of the above referenced press releases are filed as Exhibit 99.1 and Exhibit 99.2 to this Current Report on Form 8-K.
The Company is also filing the
investor presentation slides attached as Exhibit 99.3 to this Current Report on Form 8-K which the Company may use from time to time with investors and analysts. The presentation will also be available in the investor relations section of the
Companys website.
Item 9.01.
|
Financial Statements and Exhibits
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release of the Company dated May 15, 2017
|
|
|
99.2
|
|
Press Release of the Company dated May 15, 2017
|
|
|
99.3
|
|
Presentation of the Company dated May 16, 2017
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
MINERVA NEUROSCIENCES, INC.
|
|
|
By:
|
|
/s/ Mark S. Levine
|
Name:
|
|
Mark S. Levine
|
Title:
|
|
Senior Vice President, General Counsel and Secretary
|
Date: May 15, 2017
INDEX OF EXHIBITS
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release of the Company dated May 15, 2017
|
|
|
99.2
|
|
Press Release of the Company dated May 15, 2017
|
|
|
99.3
|
|
Presentation of the Company dated May 16, 2017
|
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2023 to Apr 2024